TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 6287829

Group type: EXPERIMENTAL
Intervention: Pyrantel pamoate (10 mg/kg body weight daily for 2 or 3 days)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bephenium hydroxynaphthoate (2.5 g base) and piperazine citrate (2-3 g) given daily for 2 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pyrantel pamoate (2-day and 3-day courses)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bephenium/piperazine regimen
Number of subjects: 0
Study: 30068669

Group type: EXPERIMENTAL
Intervention: Low-dose sedation (1 mg/kg propofol intravenous)
Number of subjects: 78

Group type: COMPARATOR
Intervention: No premedication
Number of subjects: 78
Study: 29070044

Group type: EXPERIMENTAL
Intervention: Neoadjuvant everolimus plus letrozole for 18 weeks
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Neoadjuvant everolimus plus letrozole
Number of subjects: 40

Group type: COMPARATOR
Intervention: Fluorouracil, epirubicin plus cyclophosphamide (FEC) for six cycles
Number of subjects: 40
Study: 24978834

Group type: EXPERIMENTAL
Intervention: Caffeine (5 mg·kg)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo (maltodextrin)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Dietary Nitrate (0.45 g)
Number of subjects: 14
Study: 24835757

Group type: EXPERIMENTAL
Intervention: Laser peripheral iridotomy (LPI) in treated eyes
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (untreated fellow eyes)
Number of subjects: 0
Study: 21562143

Group type: EXPERIMENTAL
Intervention: Low-GDP bicarbonate-lactate-buffered PD solutions (BL)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Classic glucose degradation product (GDP)-rich lactate-buffered PD solutions (L)
Number of subjects: 21
Study: 19709326

Group type: EXPERIMENTAL
Intervention: Indinavir/ritonavir or Lopinavir/ritonavir
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Nelfinavir
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Therapeutic drug monitoring
Number of subjects: 115
Study: 17069838

Group type: EXPERIMENTAL
Intervention: Electrocardiogram (ECG) analysis at baseline and annually thereafter
Number of subjects: 6595

Group type: EXPERIMENTAL
Intervention: Electrocardiogram (ECG) analysis
Number of subjects: 6595

Group type: EXPERIMENTAL
Intervention: Electrocardiogram (ECG) detection
Number of subjects: 6595
Study: 15024661

Group type: EXPERIMENTAL
Intervention: Patients with lumbar disc herniation
Number of subjects: 103

Group type: COMPARATOR
Intervention: Healthy subjects
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Patients with successful model fit
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Patients with unsuccessful model fit
Number of subjects: 103
Study: 12607793

Group type: EXPERIMENTAL
Intervention: Lansoprazole 15 mg once daily for 5 days
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg once daily for 5 days
Number of subjects: 63
Study: 9803327

Group type: EXPERIMENTAL
Intervention: Long-chain triglycerides (20% LCT)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Medium-chain triglycerides/long-chain triglycerides (20% MCT/LCT: 50/50)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo (0.9% sodium chloride, NaCl)
Number of subjects: 21
Study: 7647083

Group type: COMPARATOR
Intervention: Yohimbine 10.8 mg
Number of subjects: 10

Group type: COMPARATOR
Intervention: Clonidine 200 micrograms
Number of subjects: 10

Group type: COMPARATOR
Intervention: Clonidine 300 micrograms
Number of subjects: 10
Study: 2696020

Group type: EXPERIMENTAL
Intervention: 40 mg iron daily
Number of subjects: 458

Group type: COMPARATOR
Intervention: No supplements
Number of subjects: 458

Group type: EXPERIMENTAL
Intervention: 120 mg iron daily
Number of subjects: 458

Group type: EXPERIMENTAL
Intervention: 40 mg or 120 mg iron daily
Number of subjects: 458

Group type: EXPERIMENTAL
Intervention: Ferritin iron administration
Number of subjects: 458
Study: 326306

Group type: EXPERIMENTAL
Intervention: Cyclandelate treatment
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo administration
Number of subjects: 22
Study: 30658192

Group type: EXPERIMENTAL
Intervention: Camelina sativa oil (CSO) - 10 g of alpha-linolenic acid/day
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Fatty fish - 4 fish meals/week
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Lean fish - 4 fish meals/week
Number of subjects: 88

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 88
Study: 29927180

Group type: EXPERIMENTAL
Intervention: Diltiazem + ACEI/ARB (sustained-release diltiazem 120 mg daily)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Placebo + ACEI/ARB
Number of subjects: 106
Study: 25614148

Group type: EXPERIMENTAL
Intervention: GW870086 0.2%
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: GW870086 2%
Number of subjects: 25

Group type: COMPARATOR
Intervention: Comparator (not specified)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 24105075

Group type: EXPERIMENTAL
Intervention: EZN-2208 monotherapy (9 mg/m² on days 1, 8, and 15 every 28 days for patients with KRAS-mutant tumors)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: EZN-2208 plus cetuximab (400 mg/m² loading dose on day 1 followed by 250 mg/m² weekly starting on day 8)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Irinotecan (125 mg/m² on days 1 and 8 every 21 days) plus cetuximab (400 mg/m² loading dose on day 1 followed by 250 mg/m² weekly starting on day 8)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: EZN-2208 plus cetuximab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Irinotecan plus cetuximab
Number of subjects: 0
Study: 21666442

Group type: EXPERIMENTAL
Intervention: Pressure-support ventilation at 9.6 cm H2O
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Pressure-support ventilation at 14.9 cm H2O
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Pressure-support ventilation increase by 5 cm H2O
Number of subjects: 16
Study: 18295614

Group type: EXPERIMENTAL
Intervention: Whole Body Vibration (WBV)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Conventional Physiotherapy (PT)
Number of subjects: 27
Study: 17135989

Group type: EXPERIMENTAL
Intervention: Fluoxetine (FLX)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy (CBT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination Treatment (COMB)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 0
Study: 14579879

Group type: EXPERIMENTAL
Intervention: Prompt L-Pop self-etching adhesive plus sealant
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sealant only after phosphoric acid etch (Control)
Number of subjects: 0
Study: 11064971

Group type: EXPERIMENTAL
Intervention: Posterior stabilized tibial component
Number of subjects: 176

Group type: COMPARATOR
Intervention: Deep-dish tibial polyethylene component (Genesis II)
Number of subjects: 176
Study: 8618758

Group type: EXPERIMENTAL
Intervention: Lensectomy-vitrectomy procedures (n=72 eyes)
Number of subjects: 98

Group type: COMPARATOR
Intervention: No lensectomy-vitrectomy procedures (n=56 eyes)
Number of subjects: 98
Study: 1598875

Group type: EXPERIMENTAL
Intervention: Intravenous enalapril (1.25 mg) administered to group II patients after exercise testing.
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Exercise in group I patients.
Number of subjects: 97

Group type: COMPARATOR
Intervention: Group II patients (symptomatic heart failure) without intervention during exercise testing.
Number of subjects: 97
Study: 6692664

Group type: EXPERIMENTAL
Intervention: Histamine (0.5-4 micrograms/min)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Histamine (0.5 micrograms/min) during noradrenaline infusions
Number of subjects: 14

Group type: COMPARATOR
Intervention: Histamine with cimetidine and pyrilamine (mepyramine)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Local injections of Na131I
Number of subjects: 14
Study: 31902602

Group type: EXPERIMENTAL
Intervention: Serum 25-hydroxyvitamin D (25(OH)D)
Number of subjects: 73799
Study: 30932165

Group type: EXPERIMENTAL
Intervention: Simultaneous GBR with implant placement
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Delayed GBR followed by implant placement after 6 months
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Total gain utilizing novel biomaterials
Number of subjects: 13
Study: 30231466

Group type: EXPERIMENTAL
Intervention: Walnut group (28-56 g/day)
Number of subjects: 356

Group type: COMPARATOR
Intervention: Control group (abstained from walnuts)
Number of subjects: 356
Study: 27012997

Group type: EXPERIMENTAL
Intervention: Child Directed Interaction Training (CDIT)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 14
Study: 24685389

Group type: COMPARATOR
Intervention: Conventional therapy (3 hours of therapy per day)
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Continuous passive motion (CPM) device (2 hours daily throughout length of stay)
Number of subjects: 141
Study: 22313287

Group type: EXPERIMENTAL
Intervention: Abortive verum acupuncture (VAa)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Verum acupuncture (VAp)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Cetirizine (VC)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo interventions (PAa, PC)
Number of subjects: 20

Group type: COMPARATOR
Intervention: No-intervention control (NI)
Number of subjects: 20
Study: 19917946

Group type: EXPERIMENTAL
Intervention: Perioperative somatostatin and its analogues
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pancreaticoenterostomy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pancreaticogastrostomy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pancreaticoenteric anastomosis
Number of subjects: 0
Study: 17762452

Group type: EXPERIMENTAL
Intervention: Double-filtration plasmapheresis (DFPP)
Number of subjects: 82

Group type: COMPARATOR
Intervention: No double-filtration plasmapheresis (no-DFPP)
Number of subjects: 82
Study: 15025887

Group type: EXPERIMENTAL
Intervention: Physiological coherence condition
Number of subjects: 26

Group type: COMPARATOR
Intervention: Baseline condition of normal psychophysiologic function
Number of subjects: 26
Study: 11493132

Group type: EXPERIMENTAL
Intervention: Academic detailing (educational intervention)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control (no academic detailing)
Number of subjects: 17
Study: 9568750

Group type: EXPERIMENTAL
Intervention: Group 1 (patients with angina pectoris and significant stenosis)
Number of subjects: 964

Group type: COMPARATOR
Intervention: Group 1 (female patients)
Number of subjects: 964

Group type: COMPARATOR
Intervention: Group 1
Number of subjects: 964

Group type: COMPARATOR
Intervention: Group 1 (male subgroup)
Number of subjects: 964

Group type: EXPERIMENTAL
Intervention: Mortality during follow-up
Number of subjects: 964

Group type: EXPERIMENTAL
Intervention: Lipoprotein variables
Number of subjects: 964
Study: 7924899

Group type: EXPERIMENTAL
Intervention: Fluconazole 100 mg orally
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Itraconazole 100 mg orally
Number of subjects: 20
Study: 3413273

Group type: EXPERIMENTAL
Intervention: Aerobic exercise (AE) training for 12 weeks at 70% VO2max
Number of subjects: 36

Group type: COMPARATOR
Intervention: Strength and flexibility (SF) training for 12 weeks with no aerobic exercise
Number of subjects: 36
Study: 29552951

Group type: EXPERIMENTAL
Intervention: Low-pressure dilation (8 atm)
Number of subjects: 71

Group type: COMPARATOR
Intervention: High-pressure dilation (30 atm)
Number of subjects: 71
Study: 28488192

Group type: EXPERIMENTAL
Intervention: Green tea extract (GTE) at 5 mg/kg
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: Green tea extract (GTE) at 100 mg/kg
Number of subjects: 270

Group type: COMPARATOR
Intervention: Oxidized fish oil (OFO)
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: Oxidized fish oil (OFO) + Green tea extract (GTE)
Number of subjects: 270
Study: 25744160

Group type: EXPERIMENTAL
Intervention: Multi-component school-based intervention
Number of subjects: 307
Study: 23896011

Group type: EXPERIMENTAL
Intervention: Ibuprofen 800 mg
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Acetaminophen 1 g
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Combination of ibuprofen and acetaminophen
Number of subjects: 90

Group type: COMPARATOR
Intervention: Rescue analgesics
Number of subjects: 90
Study: 21726104

Group type: EXPERIMENTAL
Intervention: Topiramate (200 ‐ 300 mg/day)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Clozapine and Topiramate
Number of subjects: 80

Group type: COMPARATOR
Intervention: Clozapine and Placebo
Number of subjects: 80

Group type: COMPARATOR
Intervention: Clozapine and Topiramate vs Clozapine and Placebo
Number of subjects: 80
Study: 17905957

Group type: EXPERIMENTAL
Intervention: Manipulation under anaesthesia
Number of subjects: 36

Group type: COMPARATOR
Intervention: Hydrodilatation
Number of subjects: 36
Study: 15276783

Group type: EXPERIMENTAL
Intervention: 5 mg diazepam
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: 10 mg diazepam
Number of subjects: 84

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: VRSCWT
Number of subjects: 84

Group type: COMPARATOR
Intervention: Nonanxiogenic test
Number of subjects: 84
Study: 11595119

Group type: EXPERIMENTAL
Intervention: Bisphosphonates
Number of subjects: 3

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 3
Study: 9469684

Group type: EXPERIMENTAL
Intervention: Sertindole, a new atypical antipsychotic, details on dosage and duration not available
Number of subjects: 0
Study: 8031269

Group type: EXPERIMENTAL
Intervention: Zone I, stage 3 disease
Number of subjects: 2759

Group type: EXPERIMENTAL
Intervention: Zone II, stage 3+ ROP involving nine to 12 sectors of 30 degrees
Number of subjects: 2759

Group type: EXPERIMENTAL
Intervention: Zone II ROP without plus disease or zone III ROP
Number of subjects: 2759
Study: 2656346

Group type: EXPERIMENTAL
Intervention: Azathioprine (2 mg.kg‐1.day‐1)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Azathioprine
Number of subjects: 49
Study: 1219672

Group type: EXPERIMENTAL
Intervention: Fenfluramine (PACaps)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Diet
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 29747068

Group type: EXPERIMENTAL
Intervention: Participants with current romantic relationship stress (n=105)
Number of subjects: 190

Group type: COMPARATOR
Intervention: Participants without current romantic relationship stress (n=85)
Number of subjects: 190
Study: 28650922

Group type: EXPERIMENTAL
Intervention: Intervention practices
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control practices
Number of subjects: 25
Study: 26193865

Group type: EXPERIMENTAL
Intervention: Twelve‐week resistance exercise program (3 times/week; 3 sets, 6‐8 repetitions at 75‐80% of the 1‐repetition maximum)
Number of subjects: 235
Study: 24172548

Group type: EXPERIMENTAL
Intervention: Chilled saline irrigation
Number of subjects: 80

Group type: COMPARATOR
Intervention: Room temperature saline irrigation
Number of subjects: 80
Study: 21164373

Group type: EXPERIMENTAL
Intervention: Ventral fusion surgery
Number of subjects: 50

Group type: COMPARATOR
Intervention: Dorsal fusion surgery
Number of subjects: 50
Study: 19028329

Group type: COMPARATOR
Intervention: 0.25% atropine (0.25A)
Number of subjects: 71

Group type: COMPARATOR
Intervention: 0.5% atropine (0.5A)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: 0.25% atropine together with stimulation of the auricular acupoints (0.25A+E)
Number of subjects: 71
Study: 16575721

Group type: EXPERIMENTAL
Intervention: Mefloquine
Number of subjects: 243

Group type: COMPARATOR
Intervention: Chloroquine
Number of subjects: 243
Study: 15250227

Group type: COMPARATOR
Intervention: Conventional daytime CPAP titration
Number of subjects: 93

Group type: COMPARATOR
Intervention: Manual daytime CPAP titration
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Automatic daytime CPAP titration (AutoSet)
Number of subjects: 93
Study: 11162417

Group type: EXPERIMENTAL
Intervention: High dose inhaled beclomethasone dipropionate (BDP) 500 microg t.i.d. plus salbutamol 200 microg t.i.d.
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo plus salbutamol 200 microg t.i.d.
Number of subjects: 36
Study: 9895266

Group type: EXPERIMENTAL
Intervention: High-effect base group
Number of subjects: 227

Group type: COMPARATOR
Intervention: Low-effect group
Number of subjects: 227

Group type: COMPARATOR
Intervention: High-effect apex group
Number of subjects: 227
Study: 7993329

Group type: EXPERIMENTAL
Intervention: Worry
Number of subjects: 0

Group type: COMPARATOR
Intervention: Relaxation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Present-oriented mentation
Number of subjects: 0
Study: 2544132

Group type: EXPERIMENTAL
Intervention: Enalapril (substituted for digoxin)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Digoxin (continued treatment)
Number of subjects: 20
Study: 1098764

Group type: EXPERIMENTAL
Intervention: Oral testolactone
Number of subjects: 110

Group type: COMPARATOR
Intervention: Intravenous fluorouracil alone
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Combined androgen and antimetabolite therapy
Number of subjects: 110
Study: 31980290

Group type: EXPERIMENTAL
Intervention: IV labetalol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oral nifedipine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study: 31200357

Group type: EXPERIMENTAL
Intervention: Cabozantinib
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo plus best supportive care
Number of subjects: 0
Study: 27167559

Group type: EXPERIMENTAL
Intervention: Rocker shoes
Number of subjects: 16
Study: 27028002

Group type: EXPERIMENTAL
Intervention: Resistant dextrin (10 g daily for 8 weeks)
Number of subjects: 55
Study: 24075361

Group type: EXPERIMENTAL
Intervention: 40% dextrose gel 200 mg/kg
Number of subjects: 237

Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 237
Study: 21807139

Group type: EXPERIMENTAL
Intervention: Water-based therapy
Number of subjects: 11

Group type: COMPARATOR
Intervention: Land-based therapy (active control group)
Number of subjects: 11
Study: 20183539

Group type: EXPERIMENTAL
Intervention: Device-guided slow-breathing (DGB)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Spontaneous breathing (SB)
Number of subjects: 0
Study: 16418664

Group type: EXPERIMENTAL
Intervention: Mersilene mesh‐wrapped hydroxyapatite (MHA) orbital implant
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sclera‐wrapped hydroxyapatite (SHA) orbital implant
Number of subjects: 60
Study: 15459594

Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 mg/d
Number of subjects: 180

Group type: COMPARATOR
Intervention: Simvastatin 40 mg/d
Number of subjects: 180
Study: 11403808

Group type: EXPERIMENTAL
Intervention: Endovascular treatment
Number of subjects: 504

Group type: COMPARATOR
Intervention: Carotid endarterectomy (surgery)
Number of subjects: 504
Study: 9404904

Group type: EXPERIMENTAL
Intervention: Levofloxacin (500 mg qd)
Number of subjects: 469

Group type: COMPARATOR
Intervention: Ciprofloxacin (500 mg bid)
Number of subjects: 469

Group type: EXPERIMENTAL
Intervention: Levofloxacin
Number of subjects: 469

Group type: COMPARATOR
Intervention: Ciprofloxacin
Number of subjects: 469
Study: 12959299

Group type: EXPERIMENTAL
Intervention: Simvastatin 20 mg daily
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 3327149

Group type: EXPERIMENTAL
Intervention: b.i.d. (2 x 500 mg)
Number of subjects: 261

Group type: EXPERIMENTAL
Intervention: q.i.d. (4 x 250 mg)
Number of subjects: 261
Study: 30826377

Group type: EXPERIMENTAL
Intervention: Pragmatic Model for Comparator Selection in Health-Related Behavioral Trials
Number of subjects: 0
Study: 30116106

Group type: EXPERIMENTAL
Intervention: Repeated-Sprint Training (RSH)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Sprint Interval Training in Hypoxia (SIH)
Number of subjects: 11
Study: 26818599

Group type: EXPERIMENTAL
Intervention: Computer reminders integrated in electronic patient records (EPR) for PVC management
Number of subjects: 626

Group type: COMPARATOR
Intervention: Control group without computer reminders
Number of subjects: 626

Group type: EXPERIMENTAL
Intervention: Computer reminders integrated in EPR
Number of subjects: 626
Study: 24552468

Group type: EXPERIMENTAL
Intervention: LED group (7 patients) - LED device at a wavelength of 626 nm, applied for 20 min over the surgical area, three times a week for 3 weeks starting from the operation day.
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control group (8 patients) - No specific intervention details provided.
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: LED group (7 patients) - Evaluation of biochemical markers (IL-1β, TGF-β, PGE2, NO) in peri-implant crevicular fluid (PICF).
Number of subjects: 15
Study: 22767614

Group type: EXPERIMENTAL
Intervention: Chlamydia Screening Implementation programme (yearly chlamydia screening tests)
Number of subjects: 317304

Group type: COMPARATOR
Intervention: Control group (invited at the end of round two of the intervention)
Number of subjects: 317304

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 317304
Study: 19715803

Group type: EXPERIMENTAL
Intervention: Laparoscopy-assisted total gastrectomy (LATG)
Number of subjects: 131
Study: 17690595

Group type: EXPERIMENTAL
Intervention: Escitalopram (mean maximally tolerated dose: 25.0 mg, standard deviation=8.4)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 29
Study: 16303616

Group type: EXPERIMENTAL
Intervention: Captopril plus prednisone and cyclophosphamide
Number of subjects: 18

Group type: COMPARATOR
Intervention: Prednisone plus cyclophosphamide
Number of subjects: 18
Study: 11756067

Group type: EXPERIMENTAL
Intervention: Raw green banana flour (RBF) 30 g/d
Number of subjects: 17

Group type: COMPARATOR
Intervention: Cooked green banana flour (CBF) 30 g/d
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Plant-polysaccharide-free diet with RBF 30 g/d
Number of subjects: 17
Study: 9840304

Group type: COMPARATOR
Intervention: Omeprazole
Number of subjects: 310

Group type: EXPERIMENTAL
Intervention: Total fundic wrap
Number of subjects: 310

Group type: EXPERIMENTAL
Intervention: Partial fundoplication
Number of subjects: 310
Study: 7921324

Group type: EXPERIMENTAL
Intervention: Multiple telephone 24-hour dietary recalls
Number of subjects: 49

Group type: COMPARATOR
Intervention: Face-to-face 24-hour dietary recalls
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Multiple 24-hour telephone dietary recalls
Number of subjects: 49